Tomasi V, Strano A, Orlandi M, Bartolini G, Davì G, Monti D, Taddeo U, Zavagli G
Med Hypotheses. 1986 Mar;19(3):229-41. doi: 10.1016/0306-9877(86)90070-8.
Although many data regarding the biosynthesis of thromboxane A2 and prostacyclin in diabetes mellitus have recently appeared in the literature, it is not clear whether an imbalance between the generation of the two prostaglandins might be connected to the vascular complications of diabetes. In the present review we have tried to emphasize the most significant aspects of these studies and we have focused on alterations of platelet prostacyclin receptors and on the effects of circulating immune complexes on platelets of diabetics. It is likely that studies on the release of platelet derived growth factor as well as more precise definitions of its action on vessel wall cells leading to a massive release of prostacyclin, will permit us to ascertain whether an alteration in prostaglandin ratio is linked to the genesis of the vascular complications in diabetics.
尽管最近文献中出现了许多关于糖尿病患者血栓素A2和前列环素生物合成的资料，但尚不清楚这两种前列腺素生成之间的失衡是否与糖尿病的血管并发症有关。在本综述中，我们试图强调这些研究中最重要的方面，并着重关注血小板前列环素受体的改变以及循环免疫复合物对糖尿病患者血小板的影响。对血小板衍生生长因子释放的研究以及对其作用于血管壁细胞导致前列环素大量释放的更精确界定，可能会使我们确定前列腺素比例的改变是否与糖尿病患者血管并发症的发生有关。
